Posted by Michael Wonder on 11 Sep 2020
ICER publishes evidence report on targeted immune modulator therapies for ulcerative colitis
11 September 2020 - All assessed therapies provide significant health benefits, but even after rebates, all are priced at levels that exceed common thresholds for cost effectiveness.
At the upcoming September 24 virtual meeting, the California Technology Assessment Forum will review the evidence, hear further testimony from stakeholders, and deliberate over these treatments’ comparative clinical effectiveness, other potential benefits, and long-term value for money.
